SCHEMBL6135230

SCHEMBL6135230

CCCCOC1CCN(OC(=O)OC(C)(C)C)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPC P11150 1/20 0.39
LIPG Q9Y5X9 1/20 0.39
PDE4D Q08499 3/20 0.34
PDE4A P27815 2/20 0.34
PDE4B Q07343 2/20 0.34
PDE4C Q08493 2/20 0.34
EPHX2 P34913 1/20 0.33
ALDH1A1 P00352 2/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
MLNR O43193 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
HRH1 P35367 1/20 0.31
OPRM1 P35372 1/20 0.31
DRD3 P35462 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134497 0.96 EPHX2 (0.37) LIPCLIPGPDE4DPDE4APDE4B
SCHEMBL7768811 0.85 LSS (0.34) GPR119
SCHEMBL6134978 0.83 LIPG (0.43) LIPCLIPGEPHX2MLNRCHRM2
SCHEMBL5268640 0.80 PDE4D (0.49) PDE4DPDE4APDE4BPDE4CHPGD
SCHEMBL13107229 0.77 PDE4D (0.47) PDE4DPDE4APDE4BPDE4CHPGD
SCHEMBL13107602 0.75 PRMT5 (0.46) LIPCLIPGPDE4DPDE4APDE4B
SCHEMBL373475 0.75 CHRM3 (0.35) KMT2AMEN1MLNRCHRM2CHRM1
SCHEMBL27974011 0.74 PRKCA (0.31)
SCHEMBL20129276 0.74 PDE4D (0.47) PDE4DPDE4APDE4BPDE4CHPGD
SCHEMBL212033 0.74 CHRM2 (0.42) CHRM2CHRM1CHRM3HPGDGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050261177-A1 Compound ASTELLAS PHARMA INC. (JP) 2005-11-24 US disclosed
EP-1366066-A2 CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-12-03 EP disclosed
WO-2002072621-A2 CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261177-A1 Compound MANBA, MAN2B1, MAN2A1 LIPC 4656/4885LIPG 4270/4885PDE4D 3531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.